Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
18 juin 2019 08h00 HE
|
Jounce Therapeutics, Inc.
- Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE,...
Jounce Therapeutics to Present at Upcoming Investor Conferences in June
11 juin 2019 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 11, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports First Quarter 2019 Financial Results
08 mai 2019 06h30 HE
|
Jounce Therapeutics, Inc.
- New data from vopratelimab and JTX-8064 presented at AACR 2019 - - On track to initiate new Phase 2 studies of vopratelimab - - Ended the quarter with $173.2 million in cash, cash equivalents and...
Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019
01 mai 2019 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
03 avr. 2019 08h02 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting
02 avr. 2019 13h02 HE
|
Jounce Therapeutics, Inc.
- Improved PFS and OS observed in patients treated with vopratelimab who have emergence of ICOS hi CD4 T cells compared to patients with ICOS lo CD4 T cells - - ICOS hi CD4 T cells demonstrate...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
06 mars 2019 06h30 HE
|
Jounce Therapeutics, Inc.
- New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with...
Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
04 mars 2019 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019
28 févr. 2019 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting
27 févr. 2019 16h35 HE
|
Jounce Therapeutics, Inc.
ICONIC Clinical Data Demonstrates Improved PFS/OS in Patients with Emergence of JTX-2011 Mechanistic Biomarker (ICOS high CD4 T cells) Company to Host Investor Event and Live Webcast on Tuesday,...